Rankings
▼
Calendar
ZVRA (Zevra Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena
ZVRA
Zevra Therapeutics, Inc.
Mkt Cap
$618M
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$106M
Net Income (TTM)
$83M
EPS (TTM)
$1.50
Free Cash Flow (TTM)
-$2M
Gross Margin
84.5%
Op. Margin
-59.1%
Net Margin
78.2%
FCF Margin
-2.3%
P/S Ratio (TTM)
5.8x
P/E Ratio (TTM)
7.4x
YoY Rev Growth
+350.9%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$3M
$3M
-$13M
Q2 23
$8M
$8M
-$6M
Q3 23
$3M
$3M
-$15M
Q4 23
$13M
$10M
-$15M
Q1 24
$3M
$160K
-$20M
Q2 24
$4M
$876K
-$24M
Q3 24
$4M
$1M
-$27M
Q4 24
$12M
$11M
-$15M
Q1 25
$20M
$19M
-$5M
Q2 25
$26M
$14M
-$71M
Q3 25
$26M
$25M
$4M
Q4 25
$34M
$33M
$9M
marketcaparena.com
Revenue Breakdown
ZVRA
Zevra Therapeutics, Inc.
Revenue Breakdown
Q4 2025
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
63.9x
—
Q2 23
36.7x
—
Q3 23
36.7x
—
Q4 23
22.3x
—
Q1 24
22.1x
—
Q2 24
25.8x
—
Q3 24
24.9x
—
Q4 24
26.2x
—
Q1 25
15.2x
—
Q2 25
10.0x
233.8x
Q3 25
7.3x
17.5x
Q4 25
5.8x
7.4x
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$4M
-$4M
Q2 23
-$9M
-$9M
Q3 23
-$5M
-$5M
Q4 23
-$16M
-$16M
Q1 24
-$16M
-$16M
Q2 24
-$19M
-$19M
Q3 24
-$18M
-$18M
Q4 24
-$16M
-$16M
Q1 25
-$8M
-$8M
Q2 25
-$4M
-$4M
Q3 25
$5M
$4M
Q4 25
$6M
$6M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$29K
Q2 23
$23K
Q3 23
$172K
Q4 23
$72K
Q1 24
$0
Q2 24
$0
Q3 24
$0
Q4 24
$0
Q1 25
$99K
Q2 25
$213K
Q3 25
$554K
Q4 25
$31K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
-19.9%
+174.8%
Q2 23
+551.5%
-43.5%
Q3 23
+0.7%
+92.2%
Q4 23
+469.9%
+141.0%
Q1 24
+7.8%
+49.4%
Q2 24
-47.5%
+91.8%
Q3 24
+27.6%
+69.8%
Q4 24
-8.9%
-1.5%
Q1 25
+495.6%
+7.7%
Q2 25
+481.7%
+243.2%
Q3 25
+605.4%
-29.3%
Q4 25
+183.4%
-9.6%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$945K
29.8%
Q2 23
$2M
25.4%
Q3 23
$1M
47.9%
Q4 23
$3M
22.4%
Q1 24
$2M
61.9%
Q2 24
$3M
59.2%
Q3 24
$6M
166.1%
Q4 24
$4M
33.4%
Q1 25
$3M
15.3%
Q2 25
$2M
9.5%
Q3 25
$3M
10.6%
Q4 25
$4M
12.6%
marketcaparena.com
OpEx Breakdown
R&D
G&A
S&M
SG&A
Quarter
R&D
G&A
S&M
SG&A
Q1 23
$9M
—
—
$7M
Q2 23
$7M
—
—
$7M
Q3 23
$12M
—
—
$6M
Q4 23
$10M
—
—
$15M
Q1 24
$11M
—
—
$10M
Q2 24
$11M
$2M
$11M
—
Q3 24
$11M
—
—
$16M
Q4 24
$10M
$2M
$15M
—
Q1 25
$3M
—
—
$20M
Q2 25
$3M
—
—
$21M
Q3 25
$3M
—
—
$17M
Q4 25
$3M
—
—
$20M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$40M
$55M
$95M
Q2 23
$66M
$21M
$87M
Q3 23
$43M
$40M
$83M
Q4 23
$43M
$25M
$68M
Q1 24
$43M
$10M
$53M
Q2 24
$39M
$10M
$49M
Q3 24
$54M
$35M
$89M
Q4 24
$34M
$36M
$69M
Q1 25
$37M
$25M
$63M
Q2 25
$48M
$155M
$203M
Q3 25
$54M
$145M
$200M
Q4 25
$62M
$0
$62M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
34M
-0.1%
Q2 23
34M
-1.6%
Q3 23
35M
+2.4%
Q4 23
38M
+9.1%
Q1 24
42M
+10.2%
Q2 24
42M
+0.3%
Q3 24
48M
+14.1%
Q4 24
54M
+12.3%
Q1 25
54M
+0.8%
Q2 25
56M
+4.1%
Q3 25
56M
-0.7%
Q4 25
57M
+2.3%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
—
—
FY 15
—
—
FY 16
—
—
FY 17
—
—
FY 18
—
—
FY 19
—
—
FY 20
—
—
FY 21
—
—
FY 22
—
—
FY 23
$398K
69
FY 24
$400K
59
FY 25
$53K
2K
marketcaparena.com